News

City of San Antonio enacting plan to better leverage military medical assets

  The San Antonio Military Life Science Commercialization Action Plan seeks to better leverage ...

Rapamycin Holdings Treats First Humans in eRapa Clinical Trial

Featured image is of SwRI staff working in their cGMP clean room where clinical supplies of their ...

Events

Learn to Prepare IND for Small Molecule Drugs

How does a drug development program evolve from a brilliant research idea? Join Southwest Research Institute ...
News
Azaya Therapeutics Inc. to collaborate with the University of Chicago
May 6, 2014

Azaya Therapeutics has formed a research partnership with the University of Chicago to test out a new proprietary formulation of docetaxel.

By W. Scott Bailey, San Antonio Business Journal

Azaya Therapeutics has formed a research partnership with the University of Chicago to test out a new proprietary formulation of docetaxel.

Azaya Therapeutics Inc. has entered into a collaboration with the University of Chicago. Investigators at the university's Ludwig Center for Metastasis Research will work to develop a new application for Azaya's investigational drug ATI-1123.

ATI-1123 is a proprietary formulation of the chemotherapy agent docetaxel, commonly known as Taxotere. The San Antonio-based clinical-stage oncology company is seeking to determine whether a low, clinically safe dose of radiation can significantly enhance the delivery of ATI-1123 to experimental tumors in laboratory mice.

The new study, led by Dr. Stephen J. Kron and Dr. Ralph R. Weichselbaum, will also document the effects of radiation on accumulation of docetaxel in the irradiated tumors, and examine whether the combination leads to greater inhibition of tumor growth.

Azaya officials say the work with University of Chicago researchers may serve as a model for future clinical studies in cancer patients undergoing radiation therapy.

"The outcome of this study could lead to a new treatment option for cancer patients, in which our ATI-1123 liposomal docetaxel would provide a powerful means to improve the benefits of radiotherapy," says Azaya Therapeutics President and CEO Mike Dwyer. "Given the established safety of ATI-1123 on its own, we plan to test this combination in cancer patients if the results of the animal study are promising."

Over half of all cancer patients receive radiotherapy during the course of their disease. Using the radiation to direct liposomal drugs to tumors could improve the benefits of treatment to these patients," Azaya officials say.

 

Stay informed. Subscribe to BioMed SA news alerts.